Full Generic Medicine Info
Dosage/Direction for Use

Allergic conditions
Adult: As anhydrous substance: 30 mg bid.
Child: As anhydrous substance: Initially, 0.5 mg/kg bid. Optimal dose: 0.5-1 mg/kg bid.
Hepatic impairment: Initiate at 50% of the normal dose.
Should be taken with food.
Premature infants or full-term neonates. Pregnancy and lactation.
Special Precautions
May impair ability to drive and operate machinery. Angle-closure glaucoma, urinary retention, prostatic hyperplasia or pyloroduodenal obstruction; hepatic impairment. Elderly. Not for acute asthma. Children <6 yr.
Adverse Reactions
Sedation, inability to concentrate, lassitude, dizziness, hypotension, muscular weakness, incoordination. Nausea, vomiting, diarrhoea or constipation, epigastric pain. Headache, blurred vision, tinnitus, elation or depression, irritability, nightmares, anorexia, urinary retention, dry mouth, chest tightness, dysuria and tingling. Rash, urticaria. Agranulocytosis, haemolytic anaemia. Increased appetite, wt gain. Convulsions, increased transaminase, hepatitis. Dyskinetic neurological reactions (infants and young children).
Potentially Fatal: Anaphylactoid reactions, angioedema.
Symptoms: Somnolence, stupor, dyskinesia, torticollis, oculogyria, dystonia, hypertonia, hyperexcitability, agitation, mydriasis, tachycardia, bradycardia, generalised muscle spasms. Excitement, hallucinations, muscle tremors, ataxia, convulsions, dry mouth, flushed face, mydriasis, hyperpyrexia in infants and children. Coma and cardiorespiratory collapse (terminal events). Management: Symptomatic and supportive. Extrapyramidal symptoms have been successfully treated with anticholinergic agents; no specific antidote.
Drug Interactions
May enhance effects of CNS depressants e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and tranquillizers. Anticholinergic effects of atropine, TCAs, MAOIs may be enhanced. May mask signs of ototoxicity caused by aminoglycosides.
Lab Interference
May interfere with skin testing.
Oxatomide is a piperazine derivative sedating antihistamine. It also has mast-cell stabilising properties.
Absorption: Almost completely absorbed from the GI tract. Peak plasma levels within 2 hr.
Distribution: Protein-binding: 98%.
Metabolism: Hepatic via aromatic hydroxylation, oxidative N-dealkylation and conjugation.
Excretion: Mainly via faeces (60%) from the bile; via urine. Half-life: 14 hr.
Oral: Store below 25°C. Protect from light.
CIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AE06 - oxatomide ; Belongs to the class of piperazine derivatives used as systemic antihistamines.
Disclaimer: This information is independently developed by CIMS based on oxatomide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in